Welcome to our dedicated page for Alector news (Ticker: $ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alector's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alector's position in the market.
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company, will be participating in the Bank of America Securities Health Care Conference and H.C. Wainwright 2nd Annual BioConnect Investor Conference. The company's management will give presentations at these events, showcasing their work in immuno-neurology. Webcasts of the presentations will be available on the Alector website.
Alector, Inc. (Nasdaq: ALEC) reported Q1 2024 financial results with $562.1 million in cash. The company is advancing its pipeline, strengthening leadership, and expects a data readout from the INVOKE-2 Phase 2 clinical trial of AL002 for early Alzheimer’s disease in Q4 2024. Alector also has a pivotal Phase 3 trial of latozinemab in FTD-GRN and a Phase 2 trial of AL101/GSK4527226 in early AD ongoing.